Research-centric peptide and protocol reference hub
Protocol overview
Exploratory tissue repair protocol stacking BPC-157, TB-500, and GHK-Cu for soft-tissue and connective-tissue support.
Peptides that appear in this protocol, with their primary perceived effect profiles.
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
### Summary TB-500, a synthetic derivative of thymosin beta-4, is a peptide that has garnered attention for its potential role in tissue repair and regeneration. Research into TB-500 is ongoing, particularly regarding its applications in equine medicine and its implications in doping control.
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
### Summary The Glow Stack, comprising BPC-157, TB-500, and GHK-Cu, is a combination of peptides that has garnered interest for its potential roles in tissue repair, inflammation modulation, and skin health. Research into these peptides suggests various biological activities, though comprehensive clinical data on their combined effects is still limited.
Lightweight, anonymous voting on where this protocol tends to show up in people's research (not recommendations or medical guidance).
Anonymous, research-framed suggestions for how people structure this protocol in practice. No medical advice; use as inspiration, then cross-check against primary evidence.
| Variant | Stack | Dosage | Cycle | Submitted | Upvotes |
|---|---|---|---|---|---|
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 | |
Tendon rehab micro-cycle (community-style) Structured around tendon-heavy workloads. PT and sleep/nutrition changes likely contribute significantly. | BPC-157 + TB-500 + GHK-Cu + progressive PT 3x/week | BPC-157 ~250 mcg daily, TB-500 2x/week, GHK-Cu topical nightly | 8–12 weeks with deload weeks as needed | Dec 12, 2025 |
This study investigates the effects of GHK-Cu on aging in Caenorhabditis elegans, focusing on mitochondrial function and specific signaling pathways. The findings suggest a regulatory role of GHK-Cu in these biological processes. No therapeutic claims are made regarding its effects on aging in humans.
Not reported in abstract.
Not reported in abstract.
Not reported in abstract.
Not reported in abstract.
This study focuses on the synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4, which is a component of TB-500. The research is relevant due to concerns regarding the potential doping effects of this peptide. No therapeutic claims are made.
This study analyzed the presence of TB-500, a synthetic version of thymosin β₄, in equine urine and plasma using liquid chromatography-mass spectrometry. The focus was on doping control in horses, assessing how TB-500 could be detected in biological samples. No therapeutic claims are made regarding the effects of TB-500.
This study investigated the antioxidant properties and synergistic effects of copper complexes with glycyl-l-histidyl-l-lysine-hyaluronan conjugates. The specific outcomes measured included osteogenic and angiogenic effects. Not reported in abstract.
This study investigates the effects of GHK-Cu on an experimental model of colitis. The specific outcomes measured and the doses used were not detailed in the abstract. The findings suggest potential mechanisms involved in the observed effects.
This study investigates the effects of an injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide on anti-inflammatory and antioxidant properties. The specific population, dosing regimen, and outcomes measured are not detailed in the abstract. No therapeutic claims are made.
This narrative review discusses the potential effects of BPC-157 on musculoskeletal healing. The review synthesizes existing literature but does not present original research data. No specific doses or outcomes are reported in the abstract.
This paper reviews the multifunctionality and potential medical applications of the peptide BPC-157, focusing on its role in angiogenesis and the modulation of nitric oxide. The review synthesizes existing literature and patents related to BPC-157. No specific clinical trial data or numeric findings are reported in the abstract.
The paper discusses the potential roles of BPC-157 in targeting angiogenesis and the cytotoxic effects of nitric oxide. It comments on previous literature regarding the multifunctionality and possible medical applications of BPC-157. No specific outcomes or numeric findings are reported in the abstract.